Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, cipro...
Aarti Drugs reported revenue of 23.69 billion INR for fiscal year 2025, down 5.6% from fiscal year 2024, and net income of 1.68 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 6.02 billion INR, up 8.1% from a year before. India was its largest region in fiscal year 2025, with 64% of revenue. Its market capitalization was 37.72 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.